Dita Strutt

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine

Maïté Verreault, Dita Strutt, Dana Masin et al. · BMC Cancer · 2011 · 56 citations · Full text

Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors

Euan C. Ramsay, Malathi Anantha, Jason Zastre et al. · Clinical Cancer Research · 2008 · 41 citations · Full text

Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model

Emmanuel A. Ho, Maryam Osooly, Dita Strutt et al. · Journal of Pharmaceutical Sciences · 2012 · 31 citations

Nanoparticles, Nanomedicine, Two-stage Pegylation Step +5

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model

Maïté Verreault, Dita Strutt, Dana Masin et al. · Journal of Controlled Release · 2011 · 31 citations

Neuro-oncology, Nanomedicine, Lipid-based Nanoparticulate Formulation +14

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer

Nilesh A. Patankar, Dawn Waterhouse, Dita Strutt et al. · Investigational New Drugs · 2012 · 30 citations

Nanomedicine, Engineering, Liposomal Nanoparticle Formulation +7